Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Spain.
Cell Calcium. 2011 Mar;49(3):184-90. doi: 10.1016/j.ceca.2011.02.001. Epub 2011 Feb 23.
Amyloid beta (Aβ) oligomers accumulate in the brain tissue of Alzheimer disease patients and are related to disease pathogenesis. The precise mechanisms by which Aβ oligomers cause neurotoxicity remain unknown. We recently reported that Aβ oligomers cause intracellular Ca(2+) overload and neuronal death that can be prevented by NMDA receptor antagonists. This study investigated whether Aβ oligomers directly activated NMDA receptors (NMDARs) using NR1/NR2A and NR1/NR2B receptors that were heterologously expressed in Xenopus laevis oocytes. Indeed, Aβ oligomers induced inward non-desensitizing currents that were blocked in the presence of the NMDA receptor antagonists memantine, APV, and MK-801. Intriguingly, the amplitude of the responses to Aβ oligomers was greater for NR1/NR2A heteromers than for NR1/NR2B heteromers expressed in oocytes. Consistent with these findings, we observed that the increase in the cytosolic concentration of Ca(2+) induced by Aβ oligomers in cortical neurons is prevented by AP5, a broad spectrum NMDA receptor antagonist, but slightly attenuated by ifenprodil which blocks receptors with the NR2B subunit. Together, these results indicate that Aβ oligomers directly activate NMDA receptors, particularly those with the NR2A subunit, and further suggest that drugs that attenuate the activity of such receptors may prevent Aβ damage to neurons in Alzheimeŕs disease.
淀粉样蛋白β(Aβ)寡聚体在阿尔茨海默病患者的脑组织中积累,并与疾病的发病机制有关。Aβ寡聚体导致神经毒性的确切机制尚不清楚。我们最近报道,Aβ寡聚体导致细胞内 Ca(2+)过载和神经元死亡,而 NMDA 受体拮抗剂可以预防这种情况。本研究使用在非洲爪蟾卵母细胞中异源表达的 NR1/NR2A 和 NR1/NR2B 受体,研究了 Aβ寡聚体是否直接激活 NMDA 受体(NMDARs)。事实上,Aβ寡聚体诱导内向非脱敏电流,该电流在存在 NMDA 受体拮抗剂美金刚、APV 和 MK-801 时被阻断。有趣的是,Aβ寡聚体对 NR1/NR2A 异源二聚体的反应幅度大于对卵母细胞中表达的 NR1/NR2B 异源二聚体的反应幅度。与这些发现一致,我们观察到 Aβ寡聚体在皮质神经元中诱导的细胞溶质 Ca(2+)浓度增加被广谱 NMDA 受体拮抗剂 AP5 阻止,但被ifenprodil 轻度减弱,ifenprodil 可阻断具有 NR2B 亚基的受体。总之,这些结果表明 Aβ寡聚体直接激活 NMDA 受体,特别是那些具有 NR2A 亚基的受体,并进一步表明,减弱此类受体活性的药物可能预防 Aβ对阿尔茨海默病神经元的损伤。